BDX BECTON DICKINSON & CO

NYSE bd.com


$ 188.34 $ 1.70 (0.91 %)    

Tuesday, 14-Oct-2025 15:59:59 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 188.36
$ 185.50
$ 187.25 x 10
$ 191.28 x 1
$ 185.50 - $ 188.79
$ 161.47 - $ 247.99
1,180,110
na
53.99B
$ 0.49
$ 34.06
TBD
na
na ($ 0.02)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-06-2025 12-31-2024 10-Q
4 11-27-2024 09-30-2024 10-K
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-01-2024 12-31-2023 10-Q
8 11-21-2023 09-30-2023 10-K
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-02-2023 12-31-2022 10-Q
12 11-22-2022 09-30-2022 10-K
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-03-2022 12-31-2021 10-Q
16 11-24-2021 09-30-2021 10-K
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-04-2021 12-31-2020 10-Q
20 11-25-2020 09-30-2020 10-K
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-06-2020 12-31-2019 10-Q
24 11-27-2019 09-30-2019 10-K
25 08-06-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-05-2019 12-31-2018 10-Q
28 11-21-2018 09-30-2018 10-K
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-06-2018 12-31-2017 10-Q
32 11-22-2017 09-30-2017 10-K
33 08-03-2017 06-30-2017 10-Q
34 05-02-2017 03-31-2017 10-Q
35 02-02-2017 12-31-2016 10-Q
36 11-23-2016 09-30-2016 10-K
37 08-04-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-05-2016 12-31-2015 10-Q
40 11-25-2015 09-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bd-enrolls-first-patient-in-xtract-registry-to-evaluate-rotarex-catheter-for-peripheral-artery-disease-treatment

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the enrollment of t...

 bd-and-opentrons-announce-multi-year-collaboration-to-integrate-robotic-liquid-handling-capabilities-into-bd-single-cell-multiomics-instruments-automating-critical-experimental-steps

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recog...

 trump-administration-review-targets-medical-supply-chain-vulnerabilities

The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—includ...

 this-biogen-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 where-becton-dickinson-stands-with-analysts

4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE: BDX) over the past quarter, offering a diverse set o...

 rbc-capital-initiates-coverage-on-becton-dickinson-with-sector-perform-rating-announces-price-target-of-211

RBC Capital analyst Shagun Singh initiates coverage on Becton Dickinson (NYSE: BDX) with a Sector Perform rating and announc...

 becton-dickinson-announces-pharmacy-automation-partnership-with-henry-ford-health-to-develop-health-system-pharmacy

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced a pharmacy automati...

 bd-provides-update-on-voluntary-recall-of-certain-bd-alaris-pump-infusion-sets

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/bd-provides-update-voluntary-recall-certain-bd-alaristm-pum...

 tesla-stock-could-fall-90-tomorrow-fund-manager-still-wont-buy--heres-where-hes-investing-instead

A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.

 morgan-stanley-maintains-overweight-on-becton-dickinson-raises-price-target-to-197

Morgan Stanley analyst Patrick Wood maintains Becton Dickinson (NYSE:BDX) with a Overweight and raises the price target from...

 wells-fargo-maintains-equal-weight-on-becton-dickinson-raises-price-target-to-184

Wells Fargo analyst Lawrence Biegelsen maintains Becton Dickinson (NYSE:BDX) with a Equal-Weight and raises the price target...

 apple-jumps-eli-lilly-crashes-on-worst-day-in-25-years-whats-moving-markets-thursday

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove di...

 becton-dickinson-q3-beats-estimates-on-medical-device-boom

Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical and ...

 becton-dickinson-raises-fy2025-adj-eps-guidance-from-1406-1434-to-1430-1445-vs-1418-est-affirms-fy2025-sales-guidance-of-21800b-21900b-vs-21826b-est

Assumptions and Outlook for Full Year Fiscal 2025The company raised its full-year adjusted EPS guidance to $14.30 to $14.45, re...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION